$129 Million is the total value of Opus Point Partners Management, LLC's 52 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMGN | Sell | AMGEN INC | $4,076,000 | -29.8% | 27,184 | -24.0% | 3.15% | -17.9% |
| CELG | Sell | CELGENE CORP | $3,963,000 | -31.0% | 39,596 | -17.4% | 3.06% | -19.2% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $3,962,000 | -32.6% | 288,158 | -17.3% | 3.06% | -21.1% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $3,921,000 | -38.2% | 96,808 | -5.5% | 3.03% | -27.7% |
| SGEN | Sell | SEATTLE GENETICS INC | $3,857,000 | -32.4% | 109,922 | -13.5% | 2.98% | -20.9% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $3,537,000 | -43.8% | 25,405 | -22.9% | 2.73% | -34.2% |
| ILMN | Sell | ILLUMINA INC | $3,522,000 | -19.0% | 21,729 | -4.0% | 2.72% | -5.2% |
| MTD | Sell | METTLER TOLEDO INTERNATIONAL | $3,275,000 | -0.5% | 9,500 | -2.1% | 2.53% | +16.5% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $3,270,000 | -37.6% | 41,137 | -1.3% | 2.53% | -27.0% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $3,218,000 | -44.7% | 8,929 | -16.7% | 2.49% | -35.2% |
| QGEN | Sell | QIAGEN NV | $3,016,000 | -31.8% | 135,000 | -15.6% | 2.33% | -20.2% |
| VCEL | Sell | VERICEL CORP | $1,752,000 | +104.4% | 298,941 | -10.0% | 1.35% | +139.2% |
| HOLX | Sell | HOLOGIC INC | $1,335,000 | -28.1% | 38,700 | -19.4% | 1.03% | -15.9% |
| LOXO | Sell | LOXO ONCOLOGY INC | $984,000 | -42.4% | 36,000 | -40.0% | 0.76% | -32.5% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $781,000 | -65.5% | 54,000 | -32.5% | 0.60% | -59.7% |
| ACHN | Sell | ACHILLION PHARMACEUTICALS IN | $764,000 | -29.2% | 99,000 | -1.0% | 0.59% | -17.1% |
| MACK | Sell | MERRIMACK PHARMACEUTICALS IN | $753,000 | -22.2% | 90,000 | -26.5% | 0.58% | -8.9% |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $683,000 | -40.0% | 45,000 | -25.0% | 0.53% | -29.8% |
| MCRB | Sell | SERES THERAPEUTICS INC | $645,000 | -44.3% | 24,300 | -26.4% | 0.50% | -34.8% |
| ZGNX | Sell | ZOGENIX INC | $630,000 | -55.4% | 68,130 | -28.8% | 0.49% | -47.7% |
| RXDX | Sell | IGNYTA INC | $548,000 | -59.1% | 81,000 | -19.0% | 0.42% | -52.1% |
| OPHT | Sell | OPHTHOTECH CORP | $533,000 | -60.1% | 12,600 | -25.9% | 0.41% | -53.3% |
| KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $442,000 | -44.4% | 49,500 | -17.5% | 0.34% | -34.9% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $429,000 | -57.9% | 3,848 | -40.9% | 0.33% | -50.7% |
| FLDM | Sell | FLUIDIGM CORP DEL | $363,000 | -52.0% | 45,000 | -35.7% | 0.28% | -43.8% |
| GILD | Sell | GILEAD SCIENCES INC | $301,000 | -91.2% | 3,282 | -90.3% | 0.23% | -89.7% |
| RPRXZ | Exit | REPROS THERAPEUTICS INCcall | $0 | – | -98,000 | -100.0% | -0.02% | – |
| CBYL | Exit | CARBYLAN THERAPEUTICS INC | $0 | – | -17,500 | -100.0% | -0.04% | – |
| INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -30,000 | -100.0% | -0.16% | – |
| DPRX | Exit | DIPEXIUM PHARMACEUTICALS INC | $0 | – | -25,000 | -100.0% | -0.18% | – |
| DNAI | Exit | PRONAI THERAPEUTICS INC | $0 | – | -30,000 | -100.0% | -0.30% | – |
| TKAI | Exit | TOKAI PHARMACEUTICALS INC | $0 | – | -62,007 | -100.0% | -0.36% | – |
| NVAX | Exit | NOVAVAX INCput | $0 | – | -100,000 | -100.0% | -0.55% | – |
| NVAX | Exit | NOVAVAX INCcall | $0 | – | -100,000 | -100.0% | -0.55% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -30,000 | -100.0% | -0.61% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -100,000 | -100.0% | -0.68% | – |
| XNCR | Exit | XENCOR INC | $0 | – | -90,000 | -100.0% | -0.87% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -102,200 | -100.0% | -0.99% | – |
| IBB | Exit | ISHARES TRnasdq biotec etf | $0 | – | -31,600 | -100.0% | -7.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.